| Literature DB >> 28238151 |
Paul Mark Mitchell1,2,3, Sridhar Venkatapuram4, Jeff Richardson5, Angelo Iezzi5, Joanna Coast6,7.
Abstract
BACKGROUND: There is a debate in the health economics literature concerning the most appropriate way of applying Amartya Sen's capability approach in economic evaluation studies. Some suggest that quality-adjusted life years (QALYs) alone are adequate while others argue that this approach is too narrow and that direct measures of capability wellbeing provide a more extensive application of Sen's paradigm.Entities:
Mesh:
Year: 2017 PMID: 28238151 PMCID: PMC5427089 DOI: 10.1007/s40273-017-0495-3
Source DB: PubMed Journal: Pharmacoeconomics ISSN: 1170-7690 Impact factor: 4.981
Socio-demographic breakdown (%) of sample by health condition/healthy population
| Health condition | Sex | Highest education | Country of residence | Age group | Total ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Secondary level | Further/continuing | Higher level | AUS | CAN | UK | USA | 18–24 | 25–34 | 35–44 | 45–54 | 55–64 | 65+ | ||
| Arthritis | 31.3 | 35.9 | 38.8 | 25.3 | 25.5 | 21.7 | 24.8 | 28.0 | 1.4 | 5.8 | 9.2 | 22.7 | 35.6 | 25.3 | 640 |
| Asthma | 31.1 | 30.9 | 32.5 | 36.6 | 24.4 | 23.8 | 25.9 | 25.9 | 13.8 | 23.5 | 23.5 | 16.8 | 15.0 | 7.4 | 579 |
| Cancer | 39.5 | 34.1 | 33.8 | 32.1 | 26.7 | 23.9 | 23.7 | 25.6 | 1.2 | 4.0 | 8.3 | 18.4 | 37.6 | 30.5 | 577 |
| Depression | 32.6 | 34.8 | 34.7 | 30.5 | 23.7 | 23.5 | 25.6 | 27.2 | 10.2 | 25.0 | 23.0 | 24.0 | 13.8 | 4.1 | 617 |
| Diabetes | 53.7 | 34.5 | 38.2 | 27.3 | 26.2 | 22.5 | 25.1 | 26.2 | 1.4 | 7.0 | 9.8 | 23.9 | 35.3 | 22.6 | 641 |
| Hearing loss | 52.7 | 33.6 | 34.3 | 32.2 | 26.7 | 24.8 | 21.7 | 26.9 | 3.8 | 8.6 | 10.3 | 17.4 | 27.7 | 32.2 | 581 |
| Heart disease | 59.5 | 35.6 | 38.6 | 25.8 | 23.3 | 24.1 | 26.1 | 26.6 | 3.6 | 5.0 | 6.3 | 17.0 | 33.8 | 34.4 | 640 |
| Healthy | 46.8 | 37.2 | 32.1 | 30.7 | 20.7 | 27.9 | 24.2 | 27.2 | 12.6 | 19.6 | 19.6 | 18.7 | 14.5 | 15.0 | 965 |
| Total | 43.7 | 34.8 | 35.2 | 30.0 | 24.4 | 24.3 | 24.7 | 26.7 | 6.4 | 12.7 | 14.1 | 19.8 | 26.0 | 21.0 | 5240 |
AUS Australia, CAN Canada, UK United Kingdom, USA United States of America
Capability and health scores (standard deviation) for population groups
| ICECAP-A | EQ-5D | SF-6D | AQoL-8D | HUI3 | 15D | QWB | |
|---|---|---|---|---|---|---|---|
| Healthy | 0.893 (0.13) | 0.941 (0.08) | 0.802 (0.11) | 0.828 (0.15) | 0.897 (0.13) | 0.950 (0.06) | 0.764 (0.14) |
| Asthma | 0.810 (0.17) | 0.830 (0.18) | 0.700 (0.13) | 0.672 (0.21) | 0.739 (0.25) | 0.839 (0.12) | 0.627 (0.14) |
| Arthritis | 0.810 (0.17) | 0.731 (0.22) | 0.664 (0.13) | 0.624 (0.22) | 0.599 (0.27) | 0.808 (0.12) | 0.578 (0.13) |
| Cancer | 0.810 (0.18) | 0.787 (0.21) | 0.685 (0.13) | 0.655 (0.22) | 0.676 (0.27) | 0.816 (0.13) | 0.598 (0.14) |
| Depression | 0.637 (0.22) | 0.702 (0.22) | 0.603 (0.11) | 0.452 (0.19) | 0.524 (0.31) | 0.757 (0.14) | 0.538 (0.13) |
| Diabetes | 0.797 (0.19) | 0.776 (0.22) | 0.680 (0.14) | 0.636 (0.23) | 0.648 (0.29) | 0.818 (0.13) | 0.610 (0.15) |
| Hearing loss | 0.855 (0.16) | 0.872 (0.14) | 0.749 (0.12) | 0.719 (0.20) | 0.687 (0.23) | 0.875 (0.10) | 0.639 (0.12) |
| Heart disease | 0.817 (0.18) | 0.786 (0.21) | 0.690 (0.13) | 0.667 (0.23) | 0.678 (0.27) | 0.819 (0.14) | 0.607 (0.15) |
| Maximum | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Minimum | 0.000 | −0.276 | 0.301 | 0.105 | −0.343 | 0.253 | 0.151 |
| Correlation with ICECAP-A | 0.613 | 0.631 | 0.802 | 0.669 | 0.667 | 0.526 |
ICECAP-A scores on 0–1 (no capability–full capability) scale. Health scores on 0–1 (dead–full health) scale for use in QALYs
15D 15-dimension health utility instrument, AQoL-8D Assessment of Quality of Life-8 Dimensions, EQ-5D EuroQol-5 Dimensions, HUI3 Health Utilities Index Mark 3, ICECAP-A ICEpop CAPability instrument for Adults, QWB Quality of Wellbeing scale, SF-6D Short Form-6 Dimensions
Fig. 1Histogram of ICECAP-A distribution in the healthy population (n = 965). ICECAP-A ICEpop CAPability instrument for Adults
Fig. 2Histogram of ICECAP-A distribution in the health condition population (n = 4295). ICECAP-A ICEpop CAPability instrument for Adults
Regressions explaining ICECAP-A overall score (n = 5240)
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Health utility | |||||||
| EQ-5D | 0.528* | ||||||
| SF-6D | 0.794* | ||||||
| AQOL-8D | 0.655* | ||||||
| HUI3 | 0.437* | ||||||
| 15D | 0.929* | ||||||
| QWB | 0.578* | ||||||
| Arthritis | −0.087* | 0.017* | 0.024* | 0.051* | 0.036* | 0.037* | 0.018* |
| Asthma | −0.080* | −0.020* | −0.002 | 0.018* | −0.008 | 0.024* | −0.003 |
| Cancer | −0.092* | −0.017* | 0.005 | 0.032* | −0.001 | 0.027* | 0.004 |
| Depression | −0.247* | −0.122* | −0.095* | −0.010 | −0.085* | −0.071* | −0.120* |
| Diabetes | −0.098* | −0.017* | 0.002 | 0.033* | 0.003 | 0.018* | −0.009 |
| Hearing loss | −0.050* | −0.015* | −0.002 | 0.035* | 0.040* | 0.019* | 0.026* |
| Heart disease | −0.087* | −0.009 | 0.009 | 0.032* | 0.004 | 0.032* | 0.008 |
| Male | 0.000 | −0.004 | −0.012* | −0.015* | −0.001 | −0.009* | −0.016* |
| University | 0.032* | 0.012* | 0.015* | −0.008* | −0.003 | 0.003 | 0.021* |
| Dip/cert/trade | 0.017* | 0.008 | 0.012* | −0.003 | 0.005 | 0.005 | 0.018* |
| Australia | 0.033* | 0.012* | 0.023* | 0.008 | 0.016* | 0.014* | 0.026* |
| USA | 0.037* | 0.024* | 0.029* | 0.011* | 0.024* | 0.026* | 0.032* |
| Canada | 0.040* | 0.021* | 0.022* | 0.007 | 0.019* | 0.022* | 0.030* |
| Age 25–34 year | −0.008 | −0.001 | −0.011 | −0.002 | −0.002 | 0.004 | −0.013 |
| Age 35–44 year | −0.032* | −0.007 | −0.029* | −0.013 | −0.007 | −0.002 | −0.028* |
| Age 45–54 year | −0.040* | −0.001 | −0.035* | −0.015* | −0.001 | 0.003 | −0.032* |
| Age 55–64 year | −0.011 | 0.023* | −0.018* | −0.013 | 0.021* | 0.026* | −0.009 |
| Age 65+ year | 0.044* | 0.057* | 0.017 | −0.005 | 0.059* | 0.060* | 0.030* |
| Constant | 0.860* | 0.367* | 0.249* | 0.362* | 0.475* | −0.019 | 0.435* |
| Adjusted | 0.173 | 0.442 | 0.443 | 0.655 | 0.510 | 0.498 | 0.351 |
15D 15-Dimension health utility instrument, AQoL-8D Assessment of Quality of Life-8 Dimensions, EQ-5D EuroQol-5 Dimensions, HUI3 Health Utilities Index Mark 3, ICECAP-A ICEpop CAPability instrument for Adults, QWB Quality of Wellbeing scale, SF-6D Short Form-6 Dimensions
* Statistically significant where p ≤ 0.05
| This study adds empirical evidence to the debate in health economics as to whether the quality-adjusted life years (QALY) can provide a comprehensive outcome of societal welfare benefit as well as a measure of life years adjusted for health-related quality of life. |
| We find that the commonly used measures to generate QALYs, like EQ-5D and SF-6D, perform relatively poorly in explaining individual capability wellbeing, measured using the ICECAP-A capability index. |
| This study therefore casts doubt over whether QALYs as commonly constructed provide a good proxy of individuals’ broader capabilities, as has been previously argued. |